MHH Logo

"Cardiovascular Phenotyping and Translational Strategies"


Cardiovascular disease is the number-one health problem worldwide.

          Development of therapeutic approaches depends on suitable small and large animal models that replicate pathogenesis in humans.

Non-coding RNAs are novel therapeutic targets as master regulators of gene expression by controlling many physiologic and pathologic processes.

     Our primary focus is to develop synthetic antisense oligonucleotide based therapeutics targeting specific non-coding RNAs as a revolutionary pharmacological tool fighting cardiovascular diseases.



      1. Non-coding RNA based therapy of heart failure

We aim to develop and test microRNA based therapies in small and large animal models of myocardial infarction and congestive heart failure.


2. Antisense oligo pharmacology

Pharmacological characterization of synthetic non-coding RNA inhibitors



Dr. Ariana Foinquinos, Group Leader

Dr. med. vet. Sabine Samolovac

Dr. med. vet. Heike Janssen

     Markus Herkt, PhD-student

     Karina Zimmer, Technician

     Janet Remke, Technician

     Nicole Ernst, Technician